Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib

Myung-Soo KIM; Ho-Seok CHUNG; Eu-Chang HWANG; Seung-Il JUNG; Dong-Deuk KWON; Jun-Eul HWANG; Woo-Kyun BAE; Jae-Young PARK; Chang-Wook JEONG; Cheol KWAK; Cheryn SONG; Seong-Il SEO; Seok-Soo BYUN; Sung-Hoo HONG; Jinsoo CHUNG.
Journal of Korean Medical Science ; : e325-2018.
Artículo en Inglés | WPRIM | ID: wpr-718402

Documentos relacionados

  1. Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma.
  2. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis.
  3. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
  4. Novel cut-off values of time from diagnosis to systematic therapy predict the overall survival and the efficacy of targeted therapy in renal cell carcinoma: A long-term, follow-up, retrospective study.
  5. Multi-regional Sequencing Elucidates the Evolution of Clear Cell Renal Cell Carcinoma.
  6. Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium.
  7. Impact of low and high body mass index on predicting therapeutic efficacy and prognosis in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors.
  8. Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib.
  9. International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma - Meet-URO 33 study (REGAL study).
  10. Anemia in patients ≥ 75 years with metastatic clear cell renal cell carcinoma: an important poor prognostic factor in the international metastatic renal cell carcinoma database consortium model.